PK-directed Intravenous Busulfan in Combination with High-Dose Melphalan and Bortezomib as a Conditioning Regimen for Patients with Multiple Myeloma

High dose chemotherapy followed by autologous stem cell transplantation (ASCT) has a well-established role in the treatment of patients with multiple myeloma. Melphalan 200 mg/m2 (Mel200) is the most commonly used preparative regimen. Several studies have provided evidence for potential synergism and safety when combining bortezomib (Btz) or busulfan (Bu) with melphalan (Mel). We conducted a prospective phase 2 study to investigate the safety and efficacy of conditioning with PK directed intravenous (IV) Bu with Btz and Mel.

Source: Clinical Lymphoma, Myeloma and Leukemia - June 16, 2017 Category: Hematology Authors: Stefan K. Barta, Rishi Jain, Amithaba Mazumder, Jason Carter, Lawrence Almanzar, Roy Browne, Samira Shahnaz, Richard Elkind, David Kaminetzky, Ramakrishna Battini, Olga Derman, Noah Kornblum, Amit Verma, Ira Braunschweig Tags: Original Study Source Type: research